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Summary
Background Tackling severe acute malnutrition (SAM) is a global health priority. Heightened risk of non-communicable 
diseases (NCD) in children exposed to SAM at around 2 years of age is plausible in view of previously described 
consequences of other early nutritional insults. By applying developmental origins of health and disease (DOHaD) 
theory to this group, we aimed to explore the long-term eﬀ ects of SAM.
Methods We followed up 352 Malawian children (median age 9·3 years) who were still alive following SAM inpatient 
treatment between July 12, 2006, and March 7, 2007, (median age 24 months) and compared them with 217 sibling 
controls and 184 age-and-sex matched community controls. Our outcomes of interest were anthropometry, body 
composition, lung function, physical capacity (hand grip, step test, and physical activity), and blood markers of NCD 
risk. For comparisons of all outcomes, we used multivariable linear regression, adjusted for age, sex, HIV status, and 
socioeconomic status. We also adjusted for puberty in the body composition regression model.
Findings Compared with controls, children who had survived SAM had lower height-for-age Z scores (adjusted 
diﬀ erence vs community controls 0·4, 95% CI 0·6 to 0·2, p=0·001; adjusted diﬀ erence vs sibling controls 0·2, 0·0 to 
0·4, p=0·04), although they showed evidence of catch-up growth. These children also had shorter leg length (adjusted 
diﬀ erence vs community controls 2·0 cm, 1·0 to 3·0, p<0·0001; adjusted diﬀ erence vs sibling controls 1·4 cm, 
0·5 to 2·3, p=0·002), smaller mid-upper arm circumference (adjusted diﬀ erence vs community controls 5·6 mm, 
1·9 to 9·4, p=0·001; adjusted diﬀ erence vs sibling controls 5·7 mm, 2·3 to 9·1, p=0·02), calf circumference (adjusted 
diﬀ erence vs community controls 0·49 cm, 0·1 to 0·9, p=0·01; adjusted diﬀ erence vs sibling controls 0·62 cm, 
0·2 to 1·0, p=0·001), and hip circumference (adjusted diﬀ erence vs community controls 1·56 cm, 0·5 to 2·7, p=0·01; 
adjusted diﬀ erence vs sibling controls 1·83 cm, 0·8 to 2·8, p<0·0001), and less lean mass (adjusted diﬀ erence vs 
community controls –24·5, –43 to –5·5, p=0·01; adjusted diﬀ erence vs sibling controls –11·5, –29 to –6, p=0·19) than 
did either sibling or community controls. Survivors of SAM had functional deﬁ cits consisting of weaker hand grip 
(adjusted diﬀ erence vs community controls –1·7 kg, 95% CI –2·4 to –0·9, p<0·0001; adjusted diﬀ erence vs sibling 
controls 1·01 kg, 0·3 to 1·7, p=0·005,)) and fewer minutes completed of an exercise test (sibling odds ratio [OR] 1·59, 
95% CI 1·0 to 2·5, p=0·04; community OR 1·59, 95% CI 1·0 to 2·5, p=0·05). We did not detect signiﬁ cant diﬀ erences 
between cases and controls in terms of lung function, lipid proﬁ le, glucose tolerance, glycated haemoglobin A1c, 
salivary cortisol, sitting height, and head circumference.
Interpretation Our results suggest that SAM has long-term adverse eﬀ ects. Survivors show patterns of so-called thrifty 
growth, which is associated with future cardiovascular and metabolic disease. The evidence of catch-up growth and 
largely preserved cardiometabolic and pulmonary functions suggest the potential for near-full rehabilitation. Future 
follow-up should try to establish the eﬀ ects of puberty and later dietary or social transitions on these parameters, as 
well as explore how best to optimise recovery and quality of life for survivors. 
Funding The Wellcome Trust.
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Introduction
Tackling severe acute malnutrition (SAM) is a major 
global health priority, as emphasised by its inclusion in 
the Sustainable Development Goals (SDGs).1 Although 
SAM-related mortality has been well described,2 little is 
known about its long-term eﬀ ects on the health or quality 
of life of survivors. As global child mortality falls, these 
long-term considerations are becoming increasingly 
important. Generation Nutrition, a recent major 
campaign, emphasises this need to look at the long-term 
health eﬀ ects of SAM.3 For programmes and policies to 
eﬀ ectively achieve such goals, further evidence is needed.
One potential long-term outcome for individuals who 
survive SAM is an increased risk of non-communicable 
diseases (NCDs) in later life.4,5 Extensive evidence has 
linked variability in early life nutrition with adult health 
and NCDs:6 a topic referred to as developmental origins 
of health and diseases (DOHaD). Most evidence for 
DOHaD describes associations between in utero or very 
early postnatal exposures and adult NCD risk. However, 
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it is biologically plausible that the occurrence of an insult 
such as SAM during late infancy or early childhood could 
have similar lasting eﬀ ects, since crucial growth and 
development occurs beyond infancy and even into 
puberty.7 Both the physiological insult of an acute, 
extreme calorie shortage, and the rapid catch-up growth 
that occurs during and after treatment could have long-
term implications. These early life events might 
contribute to the high burden of deaths caused by 
cardiovascular disease, diabetes, and lung disease in 
low-income and middle-income countries (which 
account for 80% of the 36 million deaths globally per 
year), necessitating the need for appropriate research.8
This study aimed to explore the long-term eﬀ ects of 
SAM in children 7 years after they had been discharged 
from hospital where they were receiving treatment for 
SAM. We investigated the eﬀ ects of SAM on growth, body 
composition, functional outcomes, and risk factors for 
NCDs in a large nutrition cohort in sub-Saharan Africa.
Methods
Study design and participants
The original prospective cohort consisted of 
1024 patients admitted for treatment of SAM at the 
Moyo nutrition ward at Queen Elizabeth Central 
Hospital in Blantyre, Malawi, from July 12, 2006, to 
March 7, 2007. All patients were treated in accordance 
with the national guidelines at the time.9 This treatment 
involved admission based on National Center for Health 
Statistics (NCHS) references and initial inpatient 
stabilisation for all children by use of therapeutic milk 
followed by nutritional rehabilitation at home with 
ready-to-use therapeutic food. Detailed baseline data 
were collected as part of the PRONUT study.10 Median 
age at admission was 24 months (IQR 16–34). In a 
follow-up study at one year post-discharge (FuSAM),11 
477 (47%) children from the original cohort remained 
alive; the surviving children from this study form the 
case group for the present follow-up, the ChroSAM 
study. For comparison, we aimed to recruit one sibling 
control and one community control per child in the case 
group. The sibling control was the sibling closest in age 
to the case child, limited to children aged between 4 and 
15·9 years. The community control was deﬁ ned as a 
child living in the same community, of the same sex, 
and aged within 12 months of the case child. We selected 
community controls randomly by spinning a bottle at 
the case child’s home and enquiring door to door, 
starting from the nearest house to where the bottle 
pointed. Written informed consent was obtained from 
the children’s parent or guardian. Any children who had 
ever been treated for SAM were not eligible as controls. 
Additional assent was sought from the child if they were 
older than 13 years. Ethical approval for the study was 
granted by the Malawi College of Medicine Research 
and Ethics Committee (reference P.02/13/1342), and the 
University College London Research Ethics Committee 
(reference 4683/001).
Research in context
Evidence before this study
Very few studies have investigated the long-term implications 
of severe acute malnutrition (SAM). In a 2012 literature review, 
Bahwere and colleagues searched PubMed and Google Scholar 
using the terms “protein energy malnutrition”, “protein caloric 
malnutrition”, “severe malnutrition”, “marasmus”, 
“kwashiorkor” and “after recovery”, “post-discharge” or “long 
term”. They found eight follow-up studies describing children 
between 6 and 18 months after discharge from SAM 
treatment. The major ﬁ nding was persistent post-SAM 
stunting. Although some longer follow-up studies of SAM do 
exist, they used older case deﬁ nitions of SAM, have small 
sample sizes, or focus only on survival and linear growth. By 
contrast, many studies have conducted long-term follow-up 
for low birthweight infants and identiﬁ ed an association 
between early life nutrition and adult health, especially non-
communicable diseases (NCDs). This ﬁ eld of research is known 
as developmental origins of health and disease (DOHaD).
Added value of this study
Our study ﬁ lls an important evidence gap that has emerged 
since treatment for SAM has improved and SAM-associated 
mortality has decreased: long-term consequences increasingly 
matter. Our data following up survivors of SAM 7 years after 
discharge from hospital covered a wide range of outcomes, 
as well as recruiting both sibling and community controls. 
The results help to deﬁ ne a potential further window of 
plasticity for DOHaD because they describe the eﬀ ects of a 
nutritional insult during childhood rather than the fetal or early 
infant period.
Implications of all the evidence
We found that SAM has long-term implications for growth, 
body composition, and physical function 7 years after hospital 
discharge. Conversely, sitting height, head circumference, and 
cardiometabolic and pulmonary markers of NCD risk seem to be 
largely preserved. Combining evidence from this study with 
existing evidence for DOHaD suggests that survivors of SAM 
show traits of so-called thrifty growth. Further studies are 
needed to establish the full eﬀ ects of SAM as these individuals 
undergo puberty and encounter other potential stressors such 
as increased access to diets high in fat and sugar during 
ongoing urbanisation of Malawi. Further research is also 
needed to enable public health programming and policy makers 
to reduce long-term consequences. It is no longer suﬃ  cient for 
children aﬀ ected by SAM to just survive: interventions must 
also help them to thrive. 
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Outcomes
Our outcomes of interest were anthropometry, body 
composition, lung function, physical capacity (ie, hand 
grip strength, step test, and physical activity), school 
achievement, and blood markers of NCD risk. Exposures 
included previous admission for SAM, socioeconomic 
status, HIV, and maternal education.
Anthropometric assessments were done in 
accordance with the guidelines by Lohman and 
colleagues12 and WHO13 and were subject to quality 
control, which involved two members of the trained 
study team taking independent readings.13 Body 
composition was measured with skinfold thickness 
measured at the biceps, triceps, subscapular, and 
suprailiac sites, and by use of bioelectrical impedance 
analysis (BIA) with a Quadscan 4000 device (Bodystat, 
Douglas, Isle of Man). Usually, BIA outputs are 
converted to total body water and fat-free mass 
via population-speciﬁ c empirical equations.14 In the 
absence of a population-speciﬁ c equation, it is possible 
to assess relative hydration and lean mass by use of raw 
BIA values adjusted for height.15 Results are presented 
as resistance index (R/height) and reactance index 
(Xc/height).
Physical activity was measured in a subset (n=78) of 
children with Actilife GT3X accelerometers (ActiGraph, 
Pensacola, FL, USA). Muscle strength was measured 
with a Takei Grip-D device (Takei, Niigata, Japan). 
Physical capacity was measured with the iSTEP 
(incremental step) test.16 Lung function was measured 
with spirometry on an Easy-On PC device (ndd Medical 
Technologies, Zürich, Switzerland); quality grades were 
applied in a blinded manner by a senior respiratory 
physiologist at the Institute for Child Health of University 
College London (London, UK).17 Spirometry outcomes 
were forced expiratory volume in 1 second (FEV1), forced 
vital capacity (FVC), and the FEV1-to-FVC ratio, all 
expressed as Z scores.18 More detailed methods are 
available in the appendix (pp 9–11).
Venous blood samples to measure glycated haemo-
globin (HbA1c), lipid proﬁ le, and full blood count were 
taken after 12 h of fasting. Salivary cortisol was assessed 
about mid-morning. A subset of children (n=60) 
underwent an oral glucose tolerance test with 1·75 mg 
per kg bodyweight of Polycal glucose powder (Nutricia, 
Dublin, Ireland).19
Data collectors were not blinded to the case or control 
status of the children because of the logistics of the study. 
The HIV status of children and mothers was established 
from health passports; if status was not known or if the 
test was done before the age of 18 months, HIV testing 
was oﬀ ered by a trained counsellor. Puberty was recorded 
as a binary variable, as reported by the participant or 
guardian (onset of menarche in girls, voice change in 
boys). Socioeconomic status was derived from asset 
scores calculated with questions taken from the Malawi 
Demographic Health Survey.20
Statistical analysis
Sample size was predetermined by the cohort size and 
survival. Controls were more diﬃ  cult to recruit than 
were cases because they had no previous personal 
connection with the study team and were restricted to the 
number of eligible children in the family and community. 
However, with 320 cases, 217 sibling controls, and 
184 community controls, we calculated that the study had 
a post-hoc power of at least 90% to detect a Z score 
diﬀ erence of 0·5 between the cases and controls based 
on reference data for growth and lung function outcomes 
at the 5% level of statistical signiﬁ cance. Given that 
Z scores of 0·5 are considered clinically signiﬁ cant in 
lung function testing and that the FuSAM study showed 
a diﬀ erence in weight-for-age Z score (WAZ) of 0·55 and 
height-for-age Z score (HAZ) of 1·13 between cases and 
sibling controls,11 we deemed our sample size to be 
satisfactory. Post-hoc calculations suggested that the 
sample size was adequate for all outcomes except 
physical activity (steps per day), which was underpowered.
We did statistical analyses with Stata version 12.1. 
To calculate the WAZ, HAZ, and body-mass index 
(BMI)-for-age Z score (BAZ), we used WHO AnthroPlus, 
which includes new WHO reference curves for children 
aged 5–19 years.21 We analysed BIA data with BIA vector 
analysis, which graphically illustrates the association 
between resistance and reactance measures (phase 
angle) to give an indication of variability in hydration 
versus lean mass.22 We converted spirometry outcomes to 
See Online for appendix
 Figure 1: Recruitment of the case group
Flow diagram for showing recruitment, starting with original recruitment in 
2006 for the PRONUT study,10 followed by 1-year follow up in the FuSAM study,11 
and the present follow-up (ChroSAM).
1024 children admitted
238 deaths in hospital
117 not found
786 alive at discharge
477 known to be alive at 
1 year post-discharge
192 died
79 not found
398 found 7 years post-
discharge
46 died
320 recruited 
into ChroSAM
32 declined to 
take part
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Z scores with the Global Lung Function Initiative (GLI) 
African-American reference values, which adjust for 
height, age, sex, and ethnicity.18
In the main analysis, we compared each type of control 
with case children by use of simple and multivariable 
linear regression analysis. We included age, sex, HIV 
status, and socioeconomic status as potential confounders 
in all multivariable regressions. We also included puberty 
as a potential confounder for body composition; puberty 
and sitting height were additional potential confounders 
for lung function outcomes. We used ordered logistic 
regression to analyse diﬀ erences between cases and 
controls for time completed in the exercise test and school 
grade achieved, which we used as a measure of educational 
attainment since children in Malawi do not move to the 
next grade until they pass, irrespective of their age. 
Because anthropometry was collected for some sibling 
controls during the 1-year follow-up study,11 we used 
repeated measures mixed regression models to analyse 
longitudinal growth between cases and sibling controls 
between 1 and 7 years post-discharge. In all analyses, we 
deemed a p value of less than 0·05 as showing a statistically 
signiﬁ cant diﬀ erence between groups.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
Figure 2: Time-to-death analysis
Kaplan-Meier time-to-death curve showing probability of death for all children in the case group (A) and 
probability of death for children stratiﬁ ed by HIV serostatus (B). Numbers in parentheses are numbers of deaths.
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HIV positive
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Cases
(n=320)
Sibling control 
(n=217)
Community 
control
(n=184)
Basic demographics
Age (years) 9·3
(8·1–10·3)
10·9
(7·4–12·8)
9·1
(8·3–10·2)
Males 174 (54%) 106 (49%) 96 (52%)
Birth order 2 (1–4) 2 (2–3) 2 (1–3)
Started puberty 7/320 (2%) 14/215 (7%) 6/180 (3%)
Clinical history
HIV
Seropositive 90/320 (28%) 9/217 (4%) 5/184 (3%)
Seronegative 208/320 (65%) 130/217 (60%) 95/184 (52%)
Status unknown 22/320 (7%) 78/217 (36%) 84/184 (46%)
Visited outpatient 
clinic in past 
6 months
115/315 (37%) 56/214 (26%) 51/179 (28%)
Family
Mother died 51/303 (17%) ·· 4/160 (3%)
Father died 59/286 (21%) ·· 9/151 (6%)
Mother HIV 
positive
83/222 (37%) ·· 23/135 (17%)
Mother’s age at 
time of ChroSAM 
(years)
32 (18–62) ·· 30 (19–50)
Maternal height 
(cm)
156·9 (5·7) ·· 156·4 (5·9)
Parity 3 (3–5) ·· 4 (3–5)
Home environment ··
Unimproved 
toilets*
244/315 (77%) ·· 140/173 (81%)
Cooking inside 
with solid smoke†
47/317 (15%) ·· 21/174 (12%)
Socioeconomic status
Maternal education
None 56/309 (18%) ·· 22/173 (13%)
Primary 121/309 (39%) ·· 65/173 (38%)
Secondary 132/309 (43%) ·· 86/173 (50%)
Wealth asset quintile
1 (poorest) 67/311 (22%) ·· 30/174 (17%)
2 59/311 (19%) ·· 41/174 (24%)
3 61/311 (20%) ·· 28/174 (16%)
4 61/311 (20%) ·· 36/174 (21%)
5 (richest) 63/311 (20%) ·· 39/174 (22%)
Data are median (IQR), mean (SD), n (%) or n/N (%). Some characteristics have 
diﬀ erent denominators due to missing data. *Open pit latrine, ﬁ eld, or bush. 
†Cooking with wood or charcoal inside the home.
Table 1: Demographic and health characteristics 
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all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
Figure 1 shows the recruitment of case children; sample 
sizes diﬀ er slightly for individual outcomes, mostly 
because not everyone who was recruited and assessed in 
the ﬁ eld came for a hospital visit. Between 1 year and 
7 years post-discharge, 46 (12%) of the 398 children who 
could be found after 7 years had died; of the 46 children 
who died during this period, 25 (54%) were HIV 
seropositive, 10 (22%) had a clinically obvious disability 
(eg, cerebral palsy), and 11 (24%) had neither HIV nor 
disability. Figure 2 shows Kaplan-Meier time-to-death 
curves that are an extension of those reported previously 
in the 1 year post-discharge study.11 These curves show 
that most deaths occurred within 2 years after admission 
(ﬁ gure 2A) and that HIV had a substantial eﬀ ect on 
survival (ﬁ gure 2B). A possible explanation for the 
apparent step-up in deaths at about 90 months (7 years) 
post-admission is recall bias with respect to date of death. 
The mean mortality rate between 2008 and 2013 for 
children aged 5–9 years in this cohort was 0·014 deaths 
per 1000 person-years, which is high compared with the 
normal rate for this age group in Malawi of 0·003 deaths 
per 1000 person-years, as reported in the WHO life table.23
Table 1 shows health and demographic characteristics 
of the three study groups. Characteristics of children in 
the case group who have died and who were lost to follow-
up are given in the appendix (p 1). Children lost to follow-
up had similar basic demographics and clinical history to 
those in the case group in this study (appendix p 1).
In terms of HAZ, case children had more severe 
stunting than controls, with shorter leg length (table 2) 
but similar sitting height (results for HIV-negative 
children only are given in the appendix p 3). Community 
and sibling controls were more likely to be in a higher 
school grade than were cases after adjustment for 
age, sex, HIV status, and socioeconomic status 
(odds ratio [OR] 1·70, 95% CI 1·2–2·4, p=0·003 compared 
with community controls and OR 2·77, 95% CI 1·9–4·0, 
p<0·0001 compared with sibling controls).
In our subgroup analysis of longitudinal growth in 
cases and sibling controls between 1 and 7 years post-
discharge, cases showed a signiﬁ cant increase in HAZ 
(coeﬃ  cient 1·45, p<0·0001) over time after adjustment 
for age, sex, and HIV status. Compared with sibling 
controls, cases had larger changes in HAZ (diﬀ erence 1·1, 
p<0·0001) and WAZ (diﬀ erence 0·9, p<0·0001), 
suggesting that cases were catching up their lost WAZ 
and HAZ by growing at a faster rate than were sibling 
controls (ﬁ gure 3).
Cases (n=378) Sibling controls
(n=219)
Cases vs sibling controls Community 
controls 
(n=184)
Cases vs community controls
Adjusted diﬀ erence 
(95% CI)
p value Adjusted diﬀ erence 
(95% CI)
p value
Growth indices
WAZ –1·6 (0·9) –1·4 (1·0) –0·2 (–0·5 to 0·1) 0·16 –1·2 (0·9) 0·3 (–0·0 to 0·5) 0·06
BAZ –0·8 (0·9) –0·8 (0·9) 0·08 (–0·1 to 0·3) 0·39 –0·7 (0·9) 0·1 (–0·1 to 0·3) 0·31
HAZ –1·8 (1·2) –1·5 (1·2) 0·2 (0·0 to 0·4) 0·04 –1·3 (1·1) 0·4 (0·2 to 0·6) 0·001
Height
Standing (cm) 124·9 (9·0) 130·3 (16·8) 2·0 (0·6– 3·4) 0·004 127·4 (9·9) 2·7 (1·2 to 4·2) 0·001
Sitting (cm) 65·2 (4·4) 67·4 (7·6) 0·6 (–0·1 to 1·3) 0·07 65·9 (4·5) 0·7 (–0·1 to 1·5) 0·08
Leg length (cm) 59·9 (5·5) 63·0 (9·6) 1·4 (0·5 to 2·3) 0·002 61·6 (6·0) 2·0 (1·0 to 3·0) <0·0001
Circumferences
Head (cm) 51·1 (2·1) 52·1 (2·5) 0·1 (–0·3 to 0·5) 0·31 52·1 (1·9) 0·3 (–0·1 to 0·8) 0·12
MUAC (mm) 172 (20) 183 (29·8) 5·7 (2·3 to 9·1) 0·002 178 (22) 5·6 (1·9 to 9·4) 0·001
Calf (cm) 23·7 (2·3) 25·0 (3·5) 0·62 (0·2 to 1·0) 0·001 24·3 (2·4) 0·49 (0·1 to 0·9) 0·01
Body composition
R/height 603·5 (105·1) 567·4 (130) –11·5 (–29 to –6) 0·19 577·1 (90·7) –24·5 (–43 to –5·5) 0·01
Xc/height 52·2 (8·4) 49·7 (9·3) –0·5 (–2·1 to 1·0) 0·52 51·5 (7·8) 0·3 (–1·4 to 1·9) 0·75
Phase angle (°) 5·0 (0·7) 5·1 (0·7) 0·1 (–0·0 to 0·2) 0·16 5·1 (0·5) 0·2 (0·1 to 0·3) 0·004
Waist circumference (cm) 56·3 (4·2) 57·7 (6·4) 0·55 (–0·2 to 1·3) 0·15 56·0 (4·5) 0·08 (–0·7 to 0·9) 0·86
Hip circumference (cm) 62·3 (5·8) 65·9 (10·2) 1·83 (0·8 to 2·8) <0·0001 63·7 (6·9) 1·56 (0·5 to 2·7) 0·01
Waist-to-hip ratio 0·91 (0·1) 0·88 (0·1) –0·01 (–0·0 to 0) 0·07 0·89 (0·1) –0·02 (–0·0 to –0·0) 0·01
Data are mean (SD) unless noted otherwise. Adjusted diﬀ erences are the results of multivariable linear regression, adjusted for age, sex, HIV status, and socioeconomic status 
for all outcomes. The body composition regression model was also adjusted for puberty. Unadjusted results are presented in the appendix (pp 5–6). WAZ=weight-for-age 
Z score. BAZ=body-mass-index-for-age Z score. HAZ=height-for-age Z score. MUAC=mid-upper arm circumference. R/height=resistance index. Xc/height=reactance index.
Table 2: Diﬀ erences in growth and body composition between cases and controls 
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In our assessment of body composition (table 2), cases 
had smaller calf and mid-upper arm circumferences 
(MUAC), suggesting reduced peripheral mass compared 
with controls. Cases had smaller hip circumference 
compared with controls and larger or similar waist 
circumference, suggesting an unhealthy ratio of core to 
gluteofemoral fat. In the BIA vector analysis, cases had 
signiﬁ cantly less lean mass than did community controls, 
but similar levels to siblings after adjustment for age 
diﬀ erences (appendix p 12). Cases also had lower phase 
angles than did community controls, which is associated 
with risk of malnutrition and morbidity risk.24
Cases had signiﬁ cantly weaker hand grip strength than 
did community controls (table 3). Results for HIV-negative 
children only are presented in the appendix (p 4). Cases 
took on average 239 fewer steps per hour than did their 
sibling controls and 54 fewer steps per hour than did 
community controls; however, these diﬀ erences were not 
signiﬁ cant. Additionally, both sibling and community 
controls had greater odds of completing more minutes of 
the iStep exercise test than did cases (sibling OR 1·59, 
95% CI 1·0–2·5, p=0·04; community OR 1·59, 95% CI 
1·0–2·5, p=0·05).
Most of the other NCD risk factors that we assessed 
were not signiﬁ cantly diﬀ erent between cases and 
controls (table 3), except for diastolic blood pressure, 
which was higher for cases than for sibling controls 
(adjusted diﬀ erence 1·91 mm Hg, p=0·03). In the oral 
glucose tolerance test, three (5%) of 56 children had 
impaired fasting glycaemia and three (5%) others had 
impaired glucose tolerance; there were no diﬀ erences 
between the groups when compared with Fisher’s exact 
test (cases vs sibling controls, p=0·20; cases vs community 
controls, p=1·0).
Discussion
A follow-up study of this size and length in a setting 
where SAM is prevalent is novel,25 as is the breadth of 
outcomes investigated. Our results suggest that SAM has 
long-term adverse eﬀ ects, especially with respect to 
growth and body composition. Survivors of SAM 
continue to have signiﬁ cantly more stunting than their 
siblings and other children in their community at 7 years 
post-discharge from inpatient nutritional treatment. 
Associated functional impairments include poorer 
physical strength, poorer physical capacity, and lower 
school achievement than in controls. Our results could 
inform future interventions to address the complex links 
between wasting and stunting, which are increasingly 
being debated.26
Despite greater stunting in the case group than in 
controls, sitting height was similar across the groups, 
suggesting that torso growth has been preserved 
and limb growth compromised. Additionally, head 
circumference was similar in all groups and lung function 
and HbA1c were close to normal when compared with 
black American children in all groups.18,27 Total cholesterol 
was also within UK recommendations. Survivors of SAM 
might have undergone so-called brain-sparing—or 
thrifty—growth, whereby the growth of vital organs has 
been preserved at the cost of less vital growth.28,29
Although body composition and physical function 
outcomes suggest potentially greater risk of NCDs in 
later life,30,31 at the relatively early life stage studied, we 
found little evidence of impaired respiratory or 
cardiometabolic outcomes (apart from increased diastolic 
blood pressure). Large sitting-to-standing height ratio, 
short limb length, lower peripheral mass, and larger 
waist-to-hip ratio have all been associated with NCDs in 
adulthood, such as cardiovascular disease, diabetes, 
and hypertension.30,32–34 Peripheral fat and lean mass, 
especially in terms of greater hip circumference, are 
thought to be protective against cardiovascular disease.30 
The pattern of lower lean mass (after adjusting for 
height) and preservation of fat mass seen in children in 
the case group is similar to that seen in children born 
A Adjusted predictions of cases and sibling controls over two follow-up timepoints
B Adjusted predictions of cases and sibling controls over two follow-up timepoints
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Figure 3: Changes in anthropometry
Graphs show modelled means for WAZ (A) and HAZ (B) for siblings and cases at 1 and 7 years post-discharge. 
WAZ=weight-for-age Z score. HAZ=height-for-age Z score.
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with low birthweight35 and is an important predictor of 
physical work capacity in later life.36 The combination of 
reduced lean mass and greater stunting compared with 
controls might explain the deﬁ ciencies in physical 
function and strength seen in the survivors of SAM in 
our study.36,37 Lean mass, glucose tolerance, and activity 
levels are interlinked and have implications for later-life 
NCDs and earning potential.38,39 Weaker hand grip is also 
associated with lower bone mass, impaired cell 
membrane potential, and reduced muscle function, as 
well as all-cause early mortality, risk of malnutrition, and 
risk of NCDs.40
However, the children in the case group did show 
signs of growth recovery. Although gain in HAZ was 
minimal in the ﬁ rst year post-discharge,11 it has since 
increased. Comparing the growth of cases with that of 
sibling controls between 1 and 7 years post-discharge, 
we noted that HAZ was increasing at a steeper rate in 
cases, who were catching up to their sibling controls. 
There has been much conﬂ icting data about the 
possibility of catch-up growth in children with stunting, 
especially after the ﬁ rst 1000 days of life.41,42 In one study, 
the authors noted that both growth faltering and catch-
up growth could occur between the ages of 8 years and 
15 years, concluding that this period oﬀ ers continued 
opportunities and sustained risks for children.43 Our 
results concur with this study, suggesting that these 
survivors of SAM are on track to catch up some of their 
lost linear growth. Since their growth plates have not yet 
fused, it would be interesting to assess stunting and 
sitting height ratio after adolescence.7 Assessment of 
whether gains in height translate to functional 
improvements, such as improved school achievement,44 
will also be necessary.
The potential for catch-up growth, as well as the 
apparent preservation of vital organ functions shown by 
our spirometry and cardiometabolic results, suggests 
that there might be potential for recovery following SAM. 
Better follow-up care and post-SAM interventions might 
reverse stunting, build lost lean mass, and improve 
muscle strength and physical activity levels in SAM 
survivors, thereby improving their quality of life and 
reducing their risk of NCDs in later life. However, it is 
notable that these SAM survivors remain relatively small 
compared with the global population for this age (largest 
WAZ being only 0·48) and disrupted organ function 
might only become apparent when exposed to increased 
weight and unhealthy lifestyles,45 as seen in studies of 
low birthweight.46 With the changes in dietary trends 
occurring in many African countries,47 it is possible that, 
in the future, SAM survivors will face increasing weight 
gain and therefore potentially greater NCD risks.
Survivor bias is the most important limitation of our 
study given that only 352 of 1024 children in the original 
cohort were still alive for the present follow-up. 
Consequently, our detection of impairments in these 
Cases 
(n=378)
Sibling 
controls 
(n=219)
Cases vs sibling controls Community 
controls 
(n=184)
Cases vs community controls
Adjusted diﬀ erence 
(95% CI)
p value Adjusted diﬀ erence 
(95% CI)
p value
Cardiorespiratory function
FEV1 Z score –0·47 (1·1) –0·48 (1·0) –0·02 (–0·3 to 0·2) 0·88 –0·34 (1·1) 0·10 (–0·2 to 0·4) 0·46
FVC Z score –0·32 (1·0) –0·38 (1·1) –0·11 (–0·4 to 0·1) 0·41 –0·15 (1·1) 0·12 (–0·1 to 0·1) 0·36
FEV1/FVC ratio Z score –0·21 (0·9) –0·15 (0·9) 0·14 (–0·1 to 0·4) 0·25 –0·37 (1·0) –0·13 (–0·4 to 0·1) 0·32
Systolic blood pressure (mm Hg) 107·8 (9·5) 109·5 (11·4) –0·17 (–2·0 to 1·6) 0·86 108·3 (9·4) 0·17 (–1·8 to 2·2) 0·87
Diastolic blood pressure (mm Hg) 69·9 (8·6) 68·8 (9·6) –1·91 (–3·6 to –0·2) 0·03 68·4 (9·0) –1·60 (–3·5 to 0·3) 0·10
Physical function
Hand grip strength (kg) 12·7 (6·3) 14·8 (7·9) 1·01 (0·3 to 1·7) 0·005 13·8 (3·9) 1·68 (0·9 to 2·4) <0·0001
Steps per hour (n=78) 716·5 (413) 955·8 (361) 144·5 (–37 to 325) 0·12 770·3 (367) –6·72 (–185 to 172) 0·94
Metabolic status
Total cholesterol (mmol/L) 3·23 (0·9) 3·29 (1·0) 0·02 (–0·2 to 0·2) 0·81 3·19 (0·8) –0·08 (–0·3 to 0·1) 0·46
Total cholesterol-to-high density 
lipoprotein ratio
3·69 (1·5) 3·87 (1·9) –0·04 (–0·4 to 0·3) 0·81 3·82 (1·4) –0·13 (–0·5 to 0·3) 0·51
Baseline glucose (n=59) 4·54 (0·6) 4·81 (0·8) 0·59 (0·1 to 1·1) 0·02 4·71 (0·4) 0·25 (–0·5 to 1·0) 0·52
120 min glucose (n=56) 5·54 (1·3) 5·93 (0·9) –0·20 (–1·1 to 0·7) 0·65 6·21 (1·5) 0·13 (–1·3 to 1·6) 0·86
Salivary cortisol (nmol/L; n=82) 4·49 (1·7) 4·73 (1·8) 0·32 (–0·7 to 1·3) 0·53 5·08 (1·7) 0·77 (–0·6 to 2·1) 0·26
Glycated haemoglobin A1c (%) 5·13 (0·5) 5·17 (0·5) 0·05 (–0·1 to 0·2) 0·40 5·07 (0·5) –0·06 (–0·2 to 0·1) 0·36
Data are mean (SD) unless noted otherwise. Adjusted diﬀ erences are adjusted for age, sex, HIV status, and socioeconomic status in a linear regression model. Puberty and 
sitting height (%) are included as potential confounders for spirometry outcomes. Steps per hour, glucose tolerance, and salivary cortisol were investigated in a subsample 
with size (n) indicated. Overall fail rate (grade F) for spirometry results was 12%. Unadjusted results are presented in the appendix (pp 7–8). NCD=non-communicable disease. 
FEV1=forced expiratory volume in 1 s. FVC=forced vital capacity.
Table 3: Means and diﬀ erences in measures of NCD risk between cases and controls 
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children, the ﬁ ttest and healthiest survivors, is of particular 
concern. As general and SAM-associated mortality fall, 
and less healthy children also survive, the long-term 
consequences might become even more marked.
Second, our results might not be generalisable to all 
children currently being treated for SAM. Although the 
children in our study were all treated as inpatients 
according to NCHS admission criteria, the latest 
treatment protocols focus on outpatient care (community-
based management of acute malnutrition [CMAM]) 
wherever possible,48 and admission criteria are also now 
more inclusive.49 Because CMAM includes earlier 
treatment and slower weight gain, future survivors might 
have fewer long-term eﬀ ects. Conversely, because CMAM 
enables a better survival rate, it could lead to more long-
term adverse eﬀ ects because the most aﬀ ected children 
who would previously have died are now surviving. Long-
term follow-up of a cohort treated with CMAM is needed 
to establish which eﬀ ects dominate.
Third, sibling and community controls are not fully 
healthy. These children also have stunting although not 
as severe as in the case group. The controls are exposed 
to similar socioeconomic constraints to the case group 
and have as many hospital admissions. As the general 
health of the population improves, the eﬀ ects of SAM 
may be more noticeable.
Fourth, it is important to note that, in this observational 
study, we cannot distinguish between association and 
causality. For example, we do not know to what extent 
early stunting contributed to episodes of SAM or whether 
SAM itself provokes greater stunting.26,50
Finally, we do not have data on early life demographics, 
including exact birthweight and gestational age. These 
factors could be potential confounders, since they are 
linked to both SAM and long-term adverse outcomes.
We have identiﬁ ed enduring eﬀ ects of SAM on growth, 
body composition, and physical function, even in a 
diminished group of survivors. The absence of 
cardiometabolic or pulmonary markers of NCD risk in 
these survivors, as well as the presence of catch-up 
growth, suggest the potential for recovery with appropriate 
intervention following SAM. However, further follow-up 
is needed to establish the full eﬀ ects of SAM after puberty, 
including the additional eﬀ ects of urbanisation and 
access to diets high in fat and sugar. Interventional 
studies to explore earlier treatment and improved post-
discharge care are a priority so that future policy and 
programming can minimise any long-term adverse 
outcomes and help children who survive SAM to thrive.
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